Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

Executive Summary

A second public consultation on the review of the HTA system will be held in January to February 2024 after more than 100 stakeholder responses were received during the first consultation earlier this year.

You may also be interested in...



Australian HTA Review: Sponsors Attack Use Of Cheap Comparators, Want More Streamlined Procedures

Shortcomings in the health technology assessment system are discouraging some companies from investing in Australia, according to responses to a recent consultation on the ongoing HTA review.

Australian HTA Review Begins In Earnest With Open Consultation

Stakeholders wishing to contribute to the review of health technology assessment policies and methods will be able to do so by making online submissions or taking part in virtual forums, and should be prepared to offer experiences and examples to help pinpoint the key options for reform.

EMA Addresses Need For Guideline On Antivirals & MAbs For COVID-19

New EU guidance will cover non-clinical and clinical development, trial design, endpoints, safety issues and comparators, as well as the use of immunobridging studies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel